Clinical trials: Coronavirus Disease-2019
Covid-19, Coronavirus Disease 2019
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
The main purpose of this phase-1b, multicenter, randomized double-blind, placebo-controlled, trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of bempegaldesleukin (BEMPEG; NKTR-214) in…
- Trial name
- NCT04646044
- Testing
- Bempegaldesleukin, Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Nektar Therapeutics
COVID-19, Coronavirus Disease 2019
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.
The main purpose of this study is to understand: the symptoms of COVID-19 or influenza health-related outcomes of people with COVID-19 or influenza the effects of vaccines in people with COVID-19 or influenza.
- Conditions
- COVID-19, Coronavirus Disease 2019, Influenza
- Trial name
- NCT06163677
- Testing
- COVID-19 Vaccine
- Sponsor
- Pfizer
Malignant Solid Tumors, Coronavirus Disease 2019 (COVID-19)
An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
This is an observational study in which data from people with cancer who had the Coronavirus disease 2019 (COVID-19) are collected and studied.
- Conditions
- Malignant Solid Tumors, Coronavirus Disease 2019 (COVID-19), SARS-CoV-2 Infection
- Trial name
- ROCURS (NCT05594147)
- Testing
- Non-TKIs, Other TKIs, Regorafenib (Stivarga, BAY73- 4506)
- Where
- United States
- Volunteers
- 4,103 people
- Sponsor
- Bayer
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib in patients hospitalized with moderate-to-severe COVID-19 (based on World Health Organization [WHO]…
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05085574
- Testing
- Famotidine, Celecoxib
- Sponsor
- Leidos Life Sciences
Coronavirus Disease 2019 (COVID-19)
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in…
- Trial name
- PREVENT-HD (NCT04508023)
- Testing
- Rivaroxaban, Standard of Care (SOC)
- Where
- 17 sites in United States
- Volunteers
- 1,284 people
- Sponsor
- Janssen Research & Development, LLC
Coronavirus Disease 2019
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Popular topic：Clinical study of recombinant Novel Coronavirus vaccine (CHO cell) combined with influenza vaccine. Research purpose:Main purpose:To evaluate the immunogenicity of recombinant Novel Coronavirus vaccine (CHO cells)…
- Trial name
- NCT05107375
- Testing
- Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 299 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19, Symptoms and Signs
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III
The goal of this clinical trial is to examine the effectiveness of intranasal-administered Chlorpheniramine Maleate in COVID-19-positive participants as part of early treatment for COVID-19.
- Conditions
- COVID-19, Symptoms and Signs, COVID-19 Pandemic, Coronavirus Disease 2019
- Trial name
- ACCROS-III (NCT05886829)
- Testing
- Chlorpheniramine Maleate 0.4% Nasal Spray
- Where
- Honduras
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma
COVID-19, Coronavirus Disease 2019
SARS-CoV-2 Nucleic Acid Detection Kit Clinical Performance Study
SARS-CoV-2 Nucleic Acid Detection Kit is an In Vitro Diagnostic (IVD) medical device intended for RNA detection of SARS-CoV-2 in human specimens using multiplex real-time polymerase chain reaction (RT-PCR) technology.
- Conditions
- COVID-19, Coronavirus Disease 2019, COVID-19 Pandemic, Diagnoses Disease
- Trial name
- CPS CW008 (NCT05492227)
- Testing
- Left-overs
- Where
- Spain
- Volunteers
- 607 people, healthy volunteers welcome
- Sponsor
- TransGen Biotech Co., LTD
Coronavirus Disease 2019 COVID-19
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with severe COVID-19 under supportive care, and…
- Trial name
- NCT04341116
- Testing
- TJ003234
- Where
- 14 sites in United States
- Volunteers
- 149 people
- Sponsor
- I-Mab Biopharma US Limited
COVID-19 (Coronavirus Disease 2019)
The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult Participants
This is double-blind,randomized, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety, tolerability and drug-drug interaction of RAY1216, and the effect of food on RAY1216 Pharmacokinetics.
- Trial name
- NCT05829551
- Testing
- RAY1216 dose 1, RAY1216 dose 2, RAY1216 dose 3
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Coronavirus Disease 2019 (COVID-19), Healthy Volunteer
A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults
To evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AZD7442 in Healthy Chinese Adults. vs. placebo
- Trial name
- NCT05437289
- Testing
- AZD7442 IM, AZD7442 IV
- Where
- 2 sites in China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19, Symptoms and Signs
Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I
The goal of this clinical trial is to examine the effectiveness of intranasal-administered Chlorpheniramine Maleate in COVID-19-positive participants as part of early treatment for COVID-19.
- Conditions
- COVID-19, Symptoms and Signs, COVID-19 Pandemic, Coronavirus Disease 2019
- Trial name
- ACCROS-I (NCT05449405)
- Testing
- Chlorpheniramine Maleate 1% Nasal Spray
- Where
- Honduras
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
Coronavirus Disease 2019
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
This is a randomized, multicenter, placebo-controlled, double-blind clinical study in patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT04672564
- Testing
- Carrimycin
- Where
- 17 sites in United States, Argentina and 4 more
- Volunteers
- 93 people
- Sponsor
- Shenyang Tonglian Group CO., Ltd
Coronavirus Disease 2019 (COVID-19)
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
This study evaluates the efficacy and safety of efprezimod alfa in hospitalized adult participants who are diagnosed with coronavirus disease 2019 (COVID-19) and receiving oxygen support.
- Trial name
- SAC-COVID (NCT04317040)
- Testing
- Efprezimod alfa
- Where
- 10 sites in United States
- Volunteers
- 234 people
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
SARS-CoV 2, COVID-19
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin in adult hospitalized patients with moderate and severe COVID-19.
- Conditions
- SARS-CoV 2, COVID-19, Coronavirus Disease 2019
- Trial name
- NCT04622865
- Testing
- Masitinib, Isoquercetin, Best Supportive Care
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- AB Science
Covid19, SARS-CoV2 Infection
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.
- Conditions
- Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019
- Trial name
- NCT05047783
- Testing
- Masitinib Mesylate
- Where
- 6 sites in France, Russia and 1 more
- Volunteers
- 78 people
- Sponsor
- AB Science
Coronavirus Disease 2019
Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by…
- Trial name
- NCT04343651
- Testing
- Leronlimab (700mg)
- Where
- 12 sites in United States
- Volunteers
- 86 people
- Sponsor
- CytoDyn, Inc.
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury
Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
This was a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and efficacy of dociparstat sodium in adult patients with acute lung injury (ALI) due to Coronavirus Disease 2019 (COVID-19).
- Conditions
- Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- Trial name
- NCT04389840
- Testing
- Dociparstat sodium
- Where
- 12 sites in United States
- Volunteers
- 27 people
- Sponsor
- Jazz Pharmaceuticals
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, COVID-19 Pandemic
- Trial name
- NCT05364268
- Testing
- Diagnostic Test: Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 514 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.